Sinonasal Outcome Test-22 (SNOT-22) score is a scale with a minimum score of 0 and a maximum score of 110 based on the presence and severity of symptoms and outcomes of rhinosinusitis. Higher scores indicate worse symptoms and/or outcomes.

All subjects enrolled with SNOT-22 measurements at both baseline and 8 weeks were included. Three enrolled subjects treated with ifetroban did not have SNOT-22 measurements for both timepoints and therefore were not analyzed for this outcome.

The Asthma Control Questionnaire-7 is a scoring system with a minimum score of 0 and a maximum score of 6 based on the severity and frequency of asthma symptoms. Higher scores indicate worse control of asthma symptoms.

All subjects enrolled with Asthma Control Questionnaire-7 measurements at both baseline and 8 weeks were included. Ten enrolled subjects treated with ifetroban and 5 enrolled subjects treated with placebo did not have Asthma Control Questionnaire-7 measurements for both timepoints and therefore were not analyzed for this outcome.

The Total Nasal Symptom Score is a scoring system with a minimum score of 0 and maximum score of 15 based on severity of nasal symptoms. Higher scores indicate worse nasal symptoms.

All subjects enrolled with Total Nasal Symptom Score (morning) measurements at both baseline and 8 weeks were included. Five enrolled subjects treated with ifetroban and 9 enrolled subjects treated with placebo did not have Total Nasal Symptom Score (morning) measurements for both timepoints and therefore were not analyzed for this outcome.

Change From Baseline in Forced Expiratory Volume in 1 second (FEV1) at 8 weeks

All subjects enrolled with FEV1 measurements at both baseline and 8 weeks were included. Four enrolled subjects treated with ifetroban and 1 enrolled subject treated with placebo did not have FEV1 measurements at both times and therefore were not analyzed for this outcome.

Change From Baseline in Peak Nasal Inspiratory Flow Rate (PNIFR) at 8 weeks

All subjects enrolled with PNIFR measurements at both baseline and 8 weeks were included. Five enrolled subjects treated with ifetroban and 1 enrolled subject treated with placebo did not have PNIFR measurements for both timepoints and therefore were not analyzed for this outcome.

Change From Baseline in Fractional Exhaled Nitric Oxide (FeNO) at 8 weeks

All subjects enrolled with FeNO measurements at both baseline and 8 weeks were included. Six enrolled subjects treated with ifetroban and 2 enrolled subjects treated with placebo did not have FeNO measurements for both timepoints and therefore were not analyzed for this outcome.

The Total Nasal Symptom Score is a scale with a minimum score of 0 and maximum score of 15 based on severity of nasal symptoms. Higher scores indicate worse nasal symptoms.

All subjects enrolled with Total Nasal Symptom Score (afternoon/evening) measurements at both baseline and 8 weeks were included. Eleven enrolled subjects treated with ifetroban and 6 enrolled subjects treated with placebo did not have Total Nasal Symptom Score (afternoon/evening) measurements for both timepoints and therefore were not analyzed for this outcome.

Change From Baseline in Blood Eosinophil Count at 8 Weeks

All subjects enrolled with blood eosinophil measurements at both baseline and 8 weeks were included. Eleven enrolled subjects treated with ifetroban and 13 enrolled subjects treated with placebo did not have blood eosinophil measurements for both timepoints and therefore were not analyzed for this outcome.